Epigenetic Regulators and Cancer Precision Therapies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 180
Special Issue Editor
Interests: epigenetics; biomarker discovery; therapeutic targeting
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tumorigenesis originated from two gene alterations: a tumor suppressor gene and a proto-oncogene/oncogene. When this gene mutates, a tumor suppressor gene causes a loss or reduction in its protection. These DNA sequences of tumor suppressor genes and oncogenes, with their aberrant changes, are extensively studied in tumor disease rather than a gene switch-on and -off from external or environmental factors for the aberrant changes called epigenetics (prefix “epi-” in Greek means over, outside of, or around). The term ‘epigenetics’ refers to aberrant changes in tumor suppressor genes in the 1990s. Epigenetics was described as a “stably heritable phenotype resulting from changes in a chromosome without alterations in the DNA sequence" at a Cold Spring Harbor meeting in 2008. There are two kinds of epigenetics and epigenomics: DNA methylation and histone modification for chromosomes.
Epigenetics and epigenomics can improve our understanding of cancer development and progression, explain the regulation of gene expression, and address genomic function without the base-pair DNA sequence. This Special Issue, titled “Epigenetic Regulators and Cancer Precision Therapies”, presents a collection of contributions by outstanding researchers that focus on the fields of cancer epigenetics and epigenomics for precision treatment.
This comprehensive collection encompasses different research and clinical applications, including the following:
(1) Techniques such as
(A) Tumor tissue samples for epigenetics with this application.
(B) Small cell number for epigenetics with these analyses.
(C) Clinical epigenomic methods for clinical samples.
(2) Roles of transcription and chromatin in gene regulation and DNA modifications.
(3) Clinical and translational medicine for epigenetics and epigenomics to personalized therapy.
(4) Novel and promising therapeutic drugs for specific epigenetic treatments.
This valuable collection has the potential to significantly improve patient outcomes and guide effective interventions for this tumor disease. While epigenetic modifiers have shown promise as targets for cancer treatment, their efficacy as standard therapies remains limited. To enhance treatment, we also explore research and clinical applications for combination approaches that integrate epigenetic therapies with other anti-tumor treatments, offering a more comprehensive strategy for maximizing therapeutic outcomes. In conclusion, the study of epigenetics in cancer has unveiled intricate mechanisms and opened new avenues for drug development and clinical application. This collection of articles provides a snapshot of the latest research, encompassing diverse aspects of epigenetic regulation in cancer. We anticipate further breakthroughs that will transform the landscape of cancer treatment and improve patient outcomes.
Dr. Biaoru Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumorigenesis
- epigenetics
- epigenomics
- personalized therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
